抗凝房颤患者首次出血后出血与缺血事件的风险和时序
在两项前瞻性队列研究的3277例抗凝房颤患者中,中位随访4.08年,19.7%发生新发出血。大出血后主要复合终点(卒中、心梗或全因死亡)发生率显著升高(aHR 2.04),而临床相关非大出血无显著关联(aHR 0.94)。首次出血后停用口服抗凝药者主要复合终点发生率更高(aHR 4.46)。
要点
- 大出血后主要不良事件风险翻倍,需强化监测。
- 临床相关非大出血未显著增加主要复合终点风险。
- 出血后停用抗凝药与更高不良事件风险相关。
核心结论
- 抗凝房颤患者大出血(而非临床相关非大出血)与主要不良结局高风险相关,部分可由停用口服抗凝药解释。
- 多数事件发生在出血后较晚期,强调长期随访的重要性。
研究设计与样本
- 两项前瞻性队列研究,纳入3277例抗凝房颤患者(平均年龄72岁,28.5%女性),中位随访4.08年(IQR 2.93-5.98)。
- 出血事件按国际血栓与止血学会指南判定为大出血或临床相关非大出血,采用时间更新多变量Cox比例风险模型比较结局。
主要发现
- 646例(19.7%)发生新发出血,其中大出血297例(9.1%),临床相关非大出血418例(12.8%)。
- 任何出血 vs 无出血:主要复合终点发生率7.08 vs 4.04/100患者年(aHR 1.36,95%CI 1.16-1.61,P<0.001),出血至主要结局中位时间306天(IQR 23-832)。
- 大出血 vs 无大出血:主要复合终点发生率11.00 vs 4.06/100患者年(aHR 2.04,95%CI 1.69-2.46,P<0.001),中位时间142天(IQR 9-518)。
- 临床相关非大出血 vs 无:主要复合终点发生率5.29 vs 4.55/100患者年(aHR 0.94,95%CI 0.76-1.15,P=0.53),中位时间505天(IQR 153-1079)。
- 首次出血后停用口服抗凝药 vs 继续:主要复合终点63/89 vs 159/557例(aHR 4.46,95%CI 3.16-6.31,P<0.001)。
临床怎么用
- 对大出血后的抗凝房颤患者应加强长期监测与随访,警惕后续缺血事件。
- 临床相关非大出血后不应轻易停用口服抗凝药,需权衡血栓风险。
- 出血后停用抗凝药与不良结局高风险相关,应考虑替代抗凝策略而非直接停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To determine the risk of subsequent adverse clinical outcomes in anticoagulated patients with atrial fibrillation (AF) who experienced a new bleeding event. METHODS AND RESULTS: Anticoagulated AF patients were followed in two prospective cohort studies. Information on incident bleeding was systematically collected during yearly follow-up visits and events were adjudicated as major bleeding or clinically relevant non-major bleeding (CRNMB) according to the International Society on Thrombosis and Haemostasis guidelines. The primary outcome was a composite of stroke, myocardial infarction (MI), or all-cause death. Time-updated multivariable Cox proportional-hazards models were used to compare outcomes in patients with and without incident bleeding. Median follow-up was 4.08 years [interquartile range (IQR): 2.93-5.98]. Of the 3277 patients included (mean age 72 years, 28.5% women), 646 (19.7%) developed a new bleeding, 297 (9.1%) a major bleeding and 418 (12.8%) a CRNMB. The incidence of the primary outcome was 7.08 and 4.04 per 100 patient-years in patients with and without any bleeding [adjusted hazard ratio (aHR): 1.36, 95% confidence interval (CI): 1.16-1.61; P < 0.001; median time between a new bleeding and a primary outcome 306 days (IQR: 23-832)]. Recurrent bleeding occurred in 126 patients [incidence, 8.65 per 100 patient-years (95% CI: 7.26-10.30)]. In patients with and without a major bleeding, the incidence of the primary outcome was 11.00 and 4.06 per 100 patient-years [aHR: 2.04, 95% CI: 1.69-2.46; P < 0.001; median time to a primary outcome 142 days (IQR: 9-518)], and 59 had recurrent bleeding [11.61 per 100 patient-years (95% CI: 8.99-14.98)]. The incidence of the primary outcome was 5.29 and 4.55 in patients with and without CRNMB [aHR: 0.94, 95% CI: 0.76-1.15; P = 0.53; median time to a composite outcome 505 days (IQR: 153-1079)], and 87 had recurrent bleeding [8.43 per 100 patient-years (95% CI: 6.83-10.40)]. Patients who had their oral anticoagulation (OAC) discontinued after their first bleeding episode had a higher incidence of the primary composite than those who continued OAC (63/89 vs. 159/557 patients; aHR: 4.46, 95% CI: 3.16-6.31; P < 0.001). CONCLUSION: In anticoagulated AF patients, major bleeding but not CRNMB was associated with a high risk of adverse outcomes, part of which may be explained by OAC discontinuation. Most events occurred late after the bleeding episode, emphasizing the importance of long-term follow-up in these patients.
引用
- Meyre, Blum, Hennings, et al. Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing. Eur Heart J. 2022. PMID: 36285887. doi:10.1093/eurheartj/ehac587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。